Pfizer and Astellas Pharma’s Promising Prostate Cancer Study: A Market Game-Changer?

Pfizer Inc ((PFE)), Astellas Pharma ((ALPMY)), Astellas Pharma ((ALPMF)) announced an update on their ongoing clinical study.

Pfizer Inc. and Astellas Pharma are conducting a Phase 3 clinical study titled ‘TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER’. The study aims to assess the safety and efficacy of talazoparib combined with enzalutamide in treating men with DDR-deficient metastatic castration-sensitive prostate cancer (mCSPC), compared to a placebo plus enzalutamide.

The intervention involves administering talazoparib, a drug designed to target cancer cells with DNA repair deficiencies, alongside enzalutamide, a hormone therapy used to treat prostate cancer. The study compares this combination to a placebo plus enzalutamide.

This randomized, double-blind study follows a parallel intervention model with quadruple masking, involving participants, care providers, investigators, and outcomes assessors. The primary purpose is treatment-focused, enrolling approximately 550 participants.

The study began on May 12, 2021, with its primary completion and estimated completion dates not yet reached. The latest update was submitted on July 7, 2025, indicating ongoing progress.

For investors, the study’s outcome could significantly impact Pfizer and Astellas Pharma’s market position, particularly if the combination therapy proves effective. Success could enhance their competitive edge in the oncology market, potentially boosting stock performance and investor confidence.

The study is currently active but not recruiting, with further details accessible on the ClinicalTrials portal.